What Researchers Did
Researchers evaluated the performance of 19 On-Q pain infusion devices delivering ropivacaine while exposed to various hyperbaric pressures and compared their fluid output to a control group of 5 devices.
What They Found
The study found no significant difference in the fluid output of the On-Q pain infusion devices when exposed to hyperbaric conditions compared to the control group. Although a decrease in device output was observed over 8 to 9 hours in both groups, this reduction was not attributable to hyperbaric pressure.
What This Means for Canadian Patients
Canadian patients requiring continuous pain management via On-Q elastomeric infusion devices can safely undergo hyperbaric oxygen therapy without concerns about altered medication delivery. This suggests that the device's performance for delivering pain medication remains consistent even under the increased pressures of hyperbaric environments.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor does it involve Canadian researchers or specific Canadian health policies.
Study Limitations
A key limitation is that this was a preliminary investigation with a relatively small sample size and specific device settings, which may limit generalizability.